Biomunex to Present Preclinical Data of its MAIT Engager Platform in Immuno-Oncology at 2025 SITC Annual Meeting
Biomunex Pharmaceuticals, a French biopharmaceutical company specializing in the development of next generation immunotherapies based on the discovery and development of bispecific and multispecific antibodies, today announces presentation of preclinical data from its MAIT engager platform at the Society for Immunotherapy of Cancer’s (“SITC”) 40th Annual Meeting being held in National Harbor, USA, from November 5th-9th, 2025.
Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology
Biomunex Pharmaceuticals, a French biopharmaceutical company specialized in the development of cutting-edge therapies through the discovery and development of bi- and multi-specific antibodies for the treatment of cancer, announced today the signature of an exclusive license and exploitation agreement with Institut Curie. This agreement covers the development of a new class of antibodies, capable of specifically targeting and engaging MAIT cells to kill cancer cells. Biomunex, which was already co-inventor and a 50% co-owner of this unique innovative approach, now holds full worldwide rights.
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
Biomunex Pharmaceuticals (Biomunex), a French biopharmaceutical company that develops cutting-edge immunotherapies through the discovery and development of bi- and multi-specific antibodies, generated from the BiXAb platform, for the treatment of cancer, announced today the enrollment in 2023 of the first patient in a Phase 1 clinical trial conducted by Onward Therapeutics SA (Onward Therapeutics).
Biomunex Pharmaceuticals, a French Company Specialized in Immunotherapy, Presents the Latest Preclinical Results on Its Disruptive MAIT Cell Redirection Approach For Cancer Treatment at the 2023 AACR Annual Meeting
Biomunex Pharmaceuticals, a French biopharmaceutical company focused on the development of immunotherapies based on the discovery and development of bi- and multi-specific antibodies for the treatment of cancer, announced today that it will participate in and present new scientific data at the American Association for Cancer Research (AACR) annual meeting, which will take place from April 14th to April 19th, 2023 at the Orange County Convention Center, Orlando, Florida, USA.
